{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:01:07Z","timestamp":1791806467970,"version":"4.3.4"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T00:00:00Z","timestamp":1551225600000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Parkinson\u2019s UK","award":["J-1102"],"award-info":[{"award-number":["J-1102"]}]},{"name":"Cure Parkinson\u2019s"},{"DOI":"10.13039\/501100004922","name":"North Bristol NHS Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004922","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MedGenesis Therapeutix"},{"DOI":"10.13039\/501100004922","name":"North Bristol NHS Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004922","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Gatsby Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,1]]},"DOI":"10.1093\/brain\/awz023","type":"journal-article","created":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T15:26:15Z","timestamp":1549293975000},"page":"512-525","source":"Crossref","is-referenced-by-count":266,"title":["Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson\u2019s disease"],"prefix":"10.1093","volume":"142","author":[{"given":"Alan","family":"Whone","sequence":"first","affiliation":[{"name":"Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK"},{"name":"Neurological and Musculoskeletal Sciences Division, North Bristol NHS Trust, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Luz","sequence":"additional","affiliation":[{"name":"MedGenesis Therapeutix Inc., Victoria, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Boca","sequence":"additional","affiliation":[{"name":"Neurological and Musculoskeletal Sciences Division, North Bristol NHS Trust, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Woolley","sequence":"additional","affiliation":[{"name":"Renishaw plc, New Mills, Wotton-under-Edge, Gloucestershire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Mooney","sequence":"additional","affiliation":[{"name":"Neurological and Musculoskeletal Sciences Division, North Bristol NHS Trust, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Dharia","sequence":"additional","affiliation":[{"name":"Neurological and Musculoskeletal Sciences Division, North Bristol NHS Trust, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Broadfoot","sequence":"additional","affiliation":[{"name":"Neurological and Musculoskeletal Sciences Division, North Bristol NHS Trust, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cronin","sequence":"additional","affiliation":[{"name":"Neurological and Musculoskeletal Sciences Division, North Bristol NHS Trust, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Schroers","sequence":"additional","affiliation":[{"name":"Neurological and Musculoskeletal Sciences Division, North Bristol NHS Trust, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil U","family":"Barua","sequence":"additional","affiliation":[{"name":"Neurological and Musculoskeletal Sciences Division, North Bristol NHS Trust, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Longpre","sequence":"additional","affiliation":[{"name":"MedGenesis Therapeutix Inc., Victoria, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Lynn","family":"Barclay","sequence":"additional","affiliation":[{"name":"MedGenesis Therapeutix Inc., Victoria, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Boiko","sequence":"additional","affiliation":[{"name":"MedGenesis Therapeutix Inc., Victoria, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg A","family":"Johnson","sequence":"additional","affiliation":[{"name":"MedGenesis Therapeutix Inc., Victoria, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H Christian","family":"Fibiger","sequence":"additional","affiliation":[{"name":"MedGenesis Therapeutix Inc., Victoria, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Harrison","sequence":"additional","affiliation":[{"name":"Renishaw plc, New Mills, Wotton-under-Edge, Gloucestershire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"Lewis","sequence":"additional","affiliation":[{"name":"Renishaw plc, New Mills, Wotton-under-Edge, Gloucestershire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Pritchard","sequence":"additional","affiliation":[{"name":"Renishaw plc, New Mills, Wotton-under-Edge, Gloucestershire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Howell","sequence":"additional","affiliation":[{"name":"Renishaw plc, New Mills, Wotton-under-Edge, Gloucestershire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"Irving","sequence":"additional","affiliation":[{"name":"Renishaw plc, New Mills, Wotton-under-Edge, Gloucestershire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Johnson","sequence":"additional","affiliation":[{"name":"Renishaw plc, New Mills, Wotton-under-Edge, Gloucestershire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suk","family":"Kinch","sequence":"additional","affiliation":[{"name":"Renishaw plc, New Mills, Wotton-under-Edge, Gloucestershire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Marshall","sequence":"additional","affiliation":[{"name":"The Wales Research and Diagnostic Positron Emission Tomography Imaging Centre (PETIC), Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D","family":"Lawrence","sequence":"additional","affiliation":[{"name":"School of Psychology, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Blinder","sequence":"additional","affiliation":[{"name":"Department of Physics and Astronomy, The University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Sossi","sequence":"additional","affiliation":[{"name":"Department of Physics and Astronomy, The University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Jon","family":"Stoessl","sequence":"additional","affiliation":[{"name":"Djavad Mowafaghian Centre for Brain Health, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Skinner","sequence":"additional","affiliation":[{"name":"Renishaw plc, New Mills, Wotton-under-Edge, Gloucestershire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich","family":"Mohr","sequence":"additional","affiliation":[{"name":"MedGenesis Therapeutix Inc., Victoria, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven S","family":"Gill","sequence":"additional","affiliation":[{"name":"Neurological and Musculoskeletal Sciences Division, North Bristol NHS Trust, Bristol, UK"},{"name":"Renishaw plc, New Mills, Wotton-under-Edge, Gloucestershire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,26]]},"reference":[{"key":"key\n\t\t\t\t2019022703303879800_awz023-B1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrn812","article-title":"The GDNF family: signalling, biological functions and therapeutic value","volume":"3","author":"Airaksinen","year":"2002","journal-title":"Nat Rev Neurosci"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pharmthera.2013.01.004","article-title":"GDNF, NGF and BDNF as therapeutic options for neurodegeneration","volume":"138","author":"Allen","year":"2013","journal-title":"Pharmacol Ther"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0168-0102(00)00097-3","article-title":"The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages","volume":"36","author":"Aoi","year":"2000","journal-title":"Neurosci Res"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3109\/10717544.2014.908248","article-title":"A novel implantable catheter system with transcutaneous port for intermittent convection-enhanced delivery of carboplatin for recurrent glioblastoma","volume":"23","author":"Barua","year":"2016","journal-title":"Drug Deliv"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jneumeth.2013.02.007","article-title":"Intermittent convection-enhanced delivery to the brain through a novel transcutaneous bone-anchored port","volume":"214","author":"Barua","year":"2013","journal-title":"J Neurosci Methods"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B7","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1046\/j.1460-9568.2000.00239.x","article-title":"Inhibition of brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor expression reduces dopaminergic sprouting in the injured striatum","volume":"12","author":"Batchelor","year":"2000","journal-title":"Eur J Neurosci"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B8","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1523\/JNEUROSCI.19-05-01708.1999","article-title":"Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor","volume":"19","author":"Batchelor","year":"1999","journal-title":"J Neurosci"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B9","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jneumeth.2011.10.002","article-title":"The development of an implantable catheter system for chronic or intermittent convection-enhanced delivery","volume":"203","author":"Bienemann","year":"2012","journal-title":"J Neurosci Methods"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B10","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/mds.10463","article-title":"Transplantation in Parkinson\u2019s disease: PET changes correlate with the amount of grafted tissue","volume":"18","author":"Cochen","year":"2003","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B11","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson\u2019s disease","volume":"5","author":"de Lau","year":"2006","journal-title":"Lancet Neurol"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B12","doi-asserted-by":"crossref","first-page":"163ra56","DOI":"10.1126\/scitranslmed.3004676","article-title":"alpha-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons","volume":"4","author":"Decressac","year":"2012","journal-title":"Sci Transl Med"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B13","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1093\/brain\/awr149","article-title":"GDNF fails to exert neuroprotection in a rat {alpha}-synuclein model of Parkinson\u2019s disease","volume":"134","author":"Decressac","year":"2011","journal-title":"Brain"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B14","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/380252a0","article-title":"Functional recovery in parkinsonian monkeys treated with GDNF","volume":"380","author":"Gash","year":"1996","journal-title":"Nature"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B15","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm850","article-title":"Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease","volume":"9","author":"Gill","year":"2003","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneumeth.2013.06.008","article-title":"In vitro and in vivo testing of a novel recessed-step catheter for reflux-free convection-enhanced drug delivery to the brain","volume":"219","author":"Gill","year":"2013","journal-title":"J Neurosci Methods"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B17","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1016\/j.neuroimage.2010.01.023","article-title":"Image-guided convection-enhanced delivery of GDNF protein into monkey putamen","volume":"54","author":"Gimenez","year":"2011","journal-title":"Neuroimage"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B18","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/mds.21894","article-title":"Placebo response in Parkinson\u2019s disease: comparisons among 11 trials covering medical and surgical interventions","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"},{"issue":"Pt 10","key":"key\n\t\t\t\t2019022703303879800_awz023-B19","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/brain\/awf234","article-title":"Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys","volume":"125","author":"Grondin","year":"2002","journal-title":"Brain"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B20","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.neuropharm.2010.02.002","article-title":"Pharmacokinetics and bioactivity of glial cell line-derived factor (GDNF) and neurturin (NTN) infused into the rat brain","volume":"58","author":"Hadaczek","year":"2010","journal-title":"Neuropharmacology"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B21","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1177\/01926230701481899a","article-title":"Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) in rhesus monkeys","volume":"35","author":"Hovland","year":"2007","journal-title":"Toxicol Pathol"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B22","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/ana.25103","article-title":"Striatal dopamine in Parkinson disease: a meta-analysis of imaging studies","volume":"82","author":"Kaasinen","year":"2017","journal-title":"Ann Neurol"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/ana.24820","article-title":"Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient","volume":"81","author":"Kordower","year":"2017","journal-title":"Ann Neurol"},{"issue":"Pt 8","key":"key\n\t\t\t\t2019022703303879800_awz023-B24","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1093\/brain\/awt192","article-title":"Disease duration and the integrity of the nigrostriatal system in Parkinson\u2019s disease","volume":"136","author":"Kordower","year":"2013","journal-title":"Brain"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B25","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/1531-8249(199909)46:3<419::AID-ANA21>3.0.CO;2-Q","article-title":"Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson\u2019s disease","volume":"46","author":"Kordower","year":"1999","journal-title":"Ann Neurol"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B26","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/ana.20737","article-title":"Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease","volume":"59","author":"Lang","year":"2006","journal-title":"Ann Neurol"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jneumeth.2015.11.008","article-title":"Chronic, intermittent convection-enhanced delivery devices","volume":"259","author":"Lewis","year":"2016","journal-title":"J Neurosci Methods"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B28","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1006\/exnr.1999.7152","article-title":"Sprouting of dopaminergic axons after striatal injury: confirmation by markers not dependent on dopamine metabolism","volume":"159","author":"Liberatore","year":"1999","journal-title":"Exp Neurol"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B29","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1126\/science.8493557","article-title":"GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons","volume":"260","author":"Lin","year":"1993","journal-title":"Science"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B30","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm0705-703","article-title":"Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain","volume":"11","author":"Love","year":"2005","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B31","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1007\/s00204-018-2222-z","article-title":"Intermittent convection-enhanced delivery of GDNF into rhesus monkey putamen: absence of local or cerebellar toxicity","volume":"92","author":"Luz","year":"2018","journal-title":"Arch Toxicol"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B32","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","article-title":"Gene delivery of AAV2-neurturin for Parkinson\u2019s disease: a double-blind, randomised, controlled trial","volume":"9","author":"Marks","year":"2010","journal-title":"Lancet Neurol"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B33","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1474-4422(08)70065-6","article-title":"Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson\u2019s disease: an open-label, phase I trial","volume":"7","author":"Marks","year":"2008","journal-title":"Lancet Neurol"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B34","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1089\/hum.2011.220","article-title":"Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson\u2019s disease","volume":"23","author":"Mittermeyer","year":"2012","journal-title":"Hum Gene Ther"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0006-8993(03)02721-5","article-title":"Monoamine neuron innervation of the normal human brain: an 18F-DOPA PET study","volume":"982","author":"Moore","year":"2003","journal-title":"Brain Res"},{"issue":"Pt 11","key":"key\n\t\t\t\t2019022703303879800_awz023-B36","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1093\/brain\/awp209","article-title":"Longitudinal progression of sporadic Parkinson\u2019s disease: a multi-tracer positron emission tomography study","volume":"132","author":"Nandhagopal","year":"2009","journal-title":"Brain"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B37","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1212\/WNL.60.1.69","article-title":"Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD","volume":"60","author":"Nutt","year":"2003","journal-title":"Neurology"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B38","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1001\/archneur.62.9.1343","article-title":"Double-blind, placebo-controlled trials for surgical interventions in Parkinson disease","volume":"62","author":"Olanow","year":"2005","journal-title":"Arch Neurol"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B39","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.10720","article-title":"A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson\u2019s disease","volume":"54","author":"Olanow","year":"2003","journal-title":"Ann Neurol"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B40","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1212\/WNL.0b013e3182a55ea5","article-title":"Benefits of putaminal gdnf infusion in parkinson disease are maintained after gdnf cessation","volume":"81","author":"Patel","year":"2013","journal-title":"Neurology"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B41","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/16060","article-title":"Dopamine release from nigral transplants visualized in vivo in a Parkinson\u2019s patient","volume":"2","author":"Piccini","year":"1999","journal-title":"Nat Neurosci"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B42","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/mds.23714","article-title":"Milestones in Parkinson\u2019s disease therapeutics","volume":"26","author":"Rascol","year":"2011","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B43","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.expneurol.2006.07.015","article-title":"Point source concentration of GDNF may explain failure of phase II clinical trial","volume":"202","author":"Salvatore","year":"2006","journal-title":"Exp Neurol"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B44","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/archneurol.2009.295","article-title":"The clinically important difference on the unified Parkinson\u2019s disease rating scale","volume":"67","author":"Shulman","year":"2010","journal-title":"Arch Neurol"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B45","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3171\/jns.2005.102.2.0216","article-title":"Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor","volume":"102","author":"Slevin","year":"2005","journal-title":"J Neurosurg"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B46","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/01.WCB.0000050041.22945.3E","article-title":"Effect of dopamine loss and the metabolite 3-O-methyl-[18F]fluoro-dopa on the relation between the 18F-fluorodopa tissue input uptake rate constant Kocc and the [18F]fluorodopa plasma input uptake rate constant Ki","volume":"23","author":"Sossi","year":"2003","journal-title":"J Cereb Blood Flow Metab"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B47","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s13311-010-0007-z","article-title":"Neuroimaging in Parkinson\u2019s disease","volume":"8","author":"Stoessl","year":"2011","journal-title":"Neurotherapeutics"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B48","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.ymthe.2017.04.018","article-title":"Alpha-synuclein mRNA is not increased in sporadic PD and alpha-synuclein accumulation does not block GDNF signaling in Parkinson\u2019s disease and disease models","volume":"25","author":"Su","year":"2017","journal-title":"Mol Ther"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B49","first-page":"e56186, 1","article-title":"Clearance and toxicity of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHu GDNF) following acute convection-enhanced delivery into the striatum","volume":"8","author":"Taylor","year":"2013","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B50","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ana.10609","article-title":"Slower progression of Parkinson\u2019s disease with ropinirole versus levodopa: The REAL-PET study","volume":"54","author":"Whone","year":"2003","journal-title":"Ann Neurol"},{"key":"key\n\t\t\t\t2019022703303879800_awz023-B51","first-page":"1396","article-title":"Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys","volume":"282","author":"Zhang","year":"1997","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/brain\/article-pdf\/142\/3\/512\/27986601\/awz023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T03:31:24Z","timestamp":1551238284000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/142\/3\/512\/5365284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,26]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,2,26]]},"published-print":{"date-parts":[[2019,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awz023","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735165397.793557354","asserted-by":"object"}]},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3]]},"published":{"date-parts":[[2019,2,26]]}}}